Skip to main content
Have a personal or library account? Click to login
Role of Imaging and Biomarkers in Identifying, Monitoring, and Promoting Myocardial Recovery Cover

Role of Imaging and Biomarkers in Identifying, Monitoring, and Promoting Myocardial Recovery

Open Access
|Aug 2024

References

  1. Yan CL, Grazette L. A review of biomarker and imaging monitoring to predict heart failure recovery. Front Cardiovasc Med. 2023 Apr 6:10:1150336. doi: 10.3389/fcvm.2023.1150336
  2. Aimo A, Gaggin HK, Barison A, Emdin M, Januzzi JL Jr. Imaging, Biomarker, and Clinical Predictors of Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2019 Sep;7(9):782-794. doi: 10.1016/j.jchf.2019.06.004
  3. Lupón J, Gavidia-Bovadilla G, Ferrer E, et al. Dynamic Trajectories of Left Ventricular Ejection Fraction in Heart Failure. J Am Coll Cardiol. 2018 Aug 7;72(6):591-601. doi: 10.1016/j.jacc.2018.05.042
  4. Kim GH, Uriel N, Burkhoff D. Reverse remodelling and myocardial recovery in heart failure. Nat Rev Cardiol. 2018 Feb;15(2):83-96. doi: 10.1038/nrcardio.2017.139
  5. Chrysakis N, Xanthopoulos A, Magouliotis D, et al. Myocardial Recovery. Diagnostics (Basel). 2023 Apr 21;13(8):1504. doi: 10.3390/diagnostics13081504
  6. Hnat T, Veselka J, Honek J. Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy. ESC Hear Fail. 2022 Aug;9(4):2070-2083. doi: 10.1002/ehf2.13939
  7. Chudý M, Goncalvesová E. Prediction of Left Ventricular Reverse Remodelling: A Mini Review on Clinical Aspects. Cardiology. 2022;147(5–6):521-528. doi: 10.1159/000526986
  8. Thavendiranathan P, Negishi T, Somerset E, et al. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy. J Am Coll Cardiol. 2021 Feb 2;77(4):392-401. doi: 10.1016/j.jacc.2020.11.020
  9. Jung IH, Park JH, Lee JA, et al. Left Ventricular Global Longitudinal Strain as a Predictor for Left Ventricular Reverse Remodeling in Dilated Cardiomyopathy. J Cardiovasc Imaging. 2020 Apr;28(2):137-149. doi: 10.4250/jcvi.2019.0111
  10. Adamo L, Perry A, Novak E, Makan M, Lindman B, Mann DL. Abnormal Global Longitudinal Strain Predicts Future Deterioration of Left Ventricular Function in Heart Failure Patients With a Recovered Left Ventricular Ejection Fraction. Circ Heart Fail. 2017 Jun;10(6):e003788. doi: 10.1161/CIRCHEARTFAILURE.116.003788
  11. Hoit BD. Left atrial size and function: role in prognosis. J Am Coll Cardiol. 2014 Feb 18;63(6):493-505. doi: 10.1016/j.jacc.2013.10.055
  12. Shiba M, Kato T, Morimoto T, et al. Left atrial reverse remodeling improves risk stratification in patients with heart failure with recovered ejection fraction. Sci Rep. 2022 Mar 16;12(1):4473. doi: 10.1038/s41598-022-08630-1
  13. Torii Y, Kusunose K, Hirata Y, et al. Left Atrial Strain Associated with Functional Recovery in Patients Receiving Optimal Treatment for Heart Failure. J Am Soc Echocardiogr. 2021 Sep;34(9):966-975.e2. doi: 10.1016/j.echo.2021.03.016
  14. Yingchoncharoen T, Agarwal S, Popovi ZB, Marwick TH. Normal ranges of left ventricular strain: a meta-analysis. J Am Soc Echocardiogr. 2013 Feb;26(2):185-91. doi: 10.1016/j.echo.2012.10.008
  15. Ilardi F, D’Andrea A, D’Ascenzi F, et al. Myocardial Work by Echocardiography: Principles and Applications in Clinical Practice. J Clin Med. 2021 Sep 29;10(19):4521. doi: 10.3390/jcm10194521
  16. Moya A, Buytaert D, Penicka M, Bartunek J, Vanderheyden M. State-of-the-Art: Noninvasive Assessment of Left Ventricular Function Through Myocardial Work. J Am Soc Echocardiogr. 2023 Oct;36(10):1027-1042. doi: 10.1016/j.echo.2023.07.002
  17. Cui C, Li Y, Liu Y, et al. Association Between Echocardiographic Non-invasive Myocardial Work Indices and Myocardial Fibrosis in Patients With Dilated Cardiomyopathy. Front Cardiovasc Med. 2021 Aug 16:8:704251. doi: 10.3389/fcvm.2021.704251
  18. Marzlin N, Hays AG, Peters M, et al. Myocardial Work in Echocardiography. Circ Cardiovasc Imaging. 2023 Feb;16(2):e014419. doi: 10.1161/CIRCIMAGING.122.014419
  19. Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation. 2008 May 20;117(20):2608-16. doi: 10.1161/CIRCULATIONAHA.107.743120
  20. Marsan NA, Breithardt OA, Delgado V, Bertini M, Tops LF. Predicting response to CRT. The value of two- and three-dimensional echocardiography. Europace. 2008 Nov:10 Suppl 3:iii73-9. doi: 10.1093/europace/eun219
  21. Barison A, Aimo A, Ortalda A, et al. Late gadolinium enhancement as a predictor of functional recovery, need for defibrillator implantation and prognosis in non-ischemic dilated cardiomyopathy. Int J Cardiol. 2018 Jan 1:250:195-200. doi: 10.1016/j.ijcard.2017.10.043
  22. Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T. The Prognostic Value of Late Gadolinium-Enhanced Cardiac Magnetic Resonance Imaging in Nonischemic Dilated Cardiomyopathy: A Review and Meta-Analysis. JACC Cardiovasc Imaging. 2018 Sep;11(9):1274-1284. doi: 10.1016/j.jcmg.2018.03.006
  23. Kida K, Yoneyama K, Kobayashi Y, Takano M, Akashi YJ, Miyake F. Late gadolinium enhancement on cardiac magnetic resonance images predicts reverse remodeling in patients with nonischemic cardiomyopathy treated with carvedilol. Int J Cardiol. 2013 Sep;168(2):1588-9. doi: 10.1016/j.ijcard.2013.01.043
  24. Ikeda Y, Inomata T, Fujita T, et al. Cardiac fibrosis detected by magnetic resonance imaging on predicting time course diversity of left ventricular reverse remodeling in patients with idiopathic dilated cardiomyopathy. Heart Vessels. 2016 Nov;31(11):1817-1825. doi: 10.1007/s00380-016-0805-2
  25. Masci PG, Schuurman R, Andrea B, et al. Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study. Circ Cardiovasc Imaging. 2013 Sep;6(5):790-9. doi: 10.1161/CIRCIMAGING.113.000438
  26. Chimura M, Onishi T, Tsukishiro Y, et al. Longitudinal strain combined with delayed-enhancement magnetic resonance improves risk stratification in patients with dilated cardiomyopathy. Heart. 2017 May;103(9):679-686. doi: 10.1136/heartjnl-2016-309746
  27. Ishii S, Inomata T, Fujita T, et al. Clinical significance of endomyocardial biopsy in conjunction with cardiac magnetic resonance imaging to predict left ventricular reverse remodeling in idiopathic dilated cardiomyopathy. Heart Vessels. 2016 Dec;31(12):1960-1968. doi: 10.1007/s00380-016-0815-0
  28. Kubanek M, Sramko M, Maluskova J, et al. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. J Am Coll Cardiol. 2013 Jan 8;61(1):54-63. doi: 10.1016/j.jacc.2012.07.072
  29. Tayal U, Wage R, Newsome S, et al. Predictors of left ventricular remodelling in patients with dilated cardiomyopathy – a cardiovascular magnetic resonance study. Eur J Heart Fail. 2020 Jul;22(7):1160-1170. doi: 10.1002/ejhf.1734
  30. Ikeda Y, Inomata T, Iida Y, et al. Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy. Heart Vessels. 2016 Apr;31(4):545-54. doi: 10.1007/s00380-015-0648-2
  31. Adamo L, Perry A, Novak E, Makan M, Lindman BR, Mann DL. Abnormal Global Longitudinal Strain Predicts Future Deterioration of Left Ventricular Function in Heart Failure Patients With a Recovered Left Ventricular Ejection Fraction. Circ Heart Fail. 2017 Jun;10(6):e003788. doi: 10.1161/CIRCHEARTFAILURE.116.003788
  32. Swat SA, Cohen D, Shah SJ, et al. Baseline Longitudinal Strain Predicts Recovery of Left Ventricular Ejection Fraction in Hospitalized Patients With Nonischemic Cardiomyopathy. J Am Heart Assoc. 2018 Oct 16;7(20):e09841. doi: 10.1161/JAHA.118.009841
  33. González A, Richards AM, de Boer RA, et al. Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022 Jun;24(6):927-943. doi: 10.1002/ejhf.2493
  34. Motiwala SR, Gaggin HK. Biomarkers to Predict Reverse Remodeling and Myocardial Recovery in Heart Failure. Curr Heart Fail Rep. 2016 Oct;13(5):207-218. doi: 10.1007/s11897-016-0303-y
  35. Weiner RB, Baggish AL, Chen-Tournoux A, et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail. 2013 Mar;15(3):342-51. doi: 10.1093/eurjhf/hfs180
  36. Mohebi R, Liu Y, Piña IL, et al. Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2022 Oct 18;80(16):1529-1541. doi: 10.1016/j.jacc.2022.08.737
  37. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JACC Heart Fail. 2014 Feb;2(1):65-72. doi: 10.1016/j.jchf.2013.10.005
  38. Sato Y, Yamada T, Taniguchi R, et al. Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 2001 Jan 23;103(3):369-74. doi: 10.1161/01.cir.103.3.369
  39. O’Connor CM, Fiuzat M, Lombardi C, et al. Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. 2011 Nov;4(6):724-32. doi: 10.1161/CIRCHEARTFAILURE.111.961581
  40. Chia S, Senatore F, Raffel OC, Lee H, Wackers FJT, Jang IK. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2008 Aug;1(4):415-23. doi: 10.1016/j.jcin.2008.04.010
  41. Brooks GC, Lee BK, Rao R, et al. Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction: The PREDICTS Study. J Am Coll Cardiol. 2016 Mar 15;67(10):1186-1196. doi: 10.1016/j.jacc.2015.12.042
  42. Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008 Dec 16;52(25):2166-74. doi: 10.1016/j.jacc.2008.09.027
  43. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007 Jun;117(6):1538-49. doi: 10.1172/JCI30634
  44. Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009 Nov;2(6):684-91. doi: 10.1161/CIRCHEARTFAILURE.109.873240
  45. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003 Feb 11;107(5):721-6. doi: 10.1161/01.cir.0000047274.66749.fe
  46. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RRJ, Januzzi JL. Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail. 2009 Jul;2(4):311-9. doi: 10.1161/CIRCHEARTFAILURE.108.833707
  47. Daniels LB, Clopton P, Iqbal N, Tran K, Maisel AS. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J. 2010 Oct;160(4):721-8. doi: 10.1016/j.ahj.2010.06.033
  48. Bayes-Genis A, de Antonio M, Galán A, et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail. 2012 Jan;14(1):32-8. doi: 10.1093/eurjhf/hfr156
  49. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011 Mar;4(2):180-7. doi: 10.1161/CIRCHEARTFAILURE.110.958223
  50. Lupón J, Gaggin HK, De Antonio M, et al. Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. Int J Cardiol. 2015 Apr 1:184:337-343. doi: 10.1016/j.ijcard.2015.02.019
  51. Motiwala SR, Szymonifka J, Belcher A, et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail. 2013 Oct;15(10):1157-63. doi: 10.1093/eurjhf/hft075
  52. Lok DJ, Lok SI, Bruggink-André de la Porte PW, et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol. 2013 Feb;102(2):103-10. doi: 10.1007/s00392-012-0500-y
  53. Motiwala SR, Szymonifka J, Belcher A, et al. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. J Cardiovasc Transl Res. 2014 Mar;7(2):250-61. doi: 10.1007/s12265-013-9522-8
  54. Tang WHW, Shrestha K, Shao Z, Borowski AG, Troughton RW, Thomas JD, et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol. 2011 Aug 1;108(3):385-90. doi: 10.1016/j.amjcard.2011.03.056
  55. Weir RAP, Petrie CJ, Murphy CA, et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ Heart Fail. 2013 May;6(3):492-8. doi: 10.1161/CIRCHEARTFAILURE.112.000146
  56. Feng J, Liang L, Chen Y, et al. Big Endothelin-1 as a Predictor of Reverse Remodeling and Prognosis in Dilated Cardiomyopathy. J Clin Med. 2023 Feb 8;12(4):1363. doi: 10.3390/jcm12041363
  57. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac Fibrosis: The Fibroblast Awakens. Circ Res. 2016 Mar 18;118(6):1021-40. doi: 10.1161/CIRCRESAHA.115.306565
  58. Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet. 2010 Dec;3(6):499-506. doi: 10.1161/CIRCGENETICS.110.957415
  59. Shah P, Bristow MR, Port JD. MicroRNAs in Heart Failure, Cardiac Transplantation, and Myocardial Recovery: Biomarkers with Therapeutic Potential. Curr Heart Fail Rep. 2017 Dec;14(6):454-464. doi: 10.1007/s11897-017-0362-8
  60. Cho JY, Kim KH, Song JE, et al. Predictors of Left Ventricular Functional Recovery and Their Impact on Clinical Outcomes in Patients With Newly Diagnosed Dilated Cardiomyopathy and Heart Failure. Heart Lung Circ. 2018 Jan;27(1):41-49. doi: 10.1016/j.hlc.2017.02.013
  61. Daubert MA, Adams K, Yow E, et al. NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF. JACC Heart Fail. 2019 Feb;7(2):158-168. doi: 10.1016/j.jchf.2018.10.014
  62. Januzzi JL Jr, Prescott MF, Butler J, et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019 Sep 17;322(11):1085-1095. doi: 10.1001/jama.2019.12821
  63. Miller WL, Hartman KA, Burritt MF, Grill DE, Jaffe AS. Profiles of serial changes in cardiac troponin T concentrations and outcome in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2009 Oct 27;54(18):1715-21. doi: 10.1016/j.jacc.2009.07.025
  64. Felker GM, Hasselblad V, Tang WHW, et al. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. Eur J Heart Fail. 2012 Nov;14(11):1257-64. doi: 10.1093/eurjhf/hfs110
  65. Felker GM, Mentz RJ, Teerlink JR, et al. Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. Eur J Heart Fail. 2015 Dec;17(12):1262-70. doi: 10.1002/ejhf.341
  66. Lupón J, Gaggin HK, de Antonio M, et al. Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. Int J Cardiol. 2015 Apr 1:184:337-343. doi: 10.1016/j.ijcard.2015.02.019
DOI: https://doi.org/10.14797/mdcvj.1381 | Journal eISSN: 1947-6108
Language: English
Page range: 42 - 53
Submitted on: Mar 24, 2024
Accepted on: Jun 22, 2024
Published on: Aug 20, 2024
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2024 Evelyne Meekers, Matthias Dupont, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.